Peloton Wealth Strategists Cuts Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Peloton Wealth Strategists lowered its position in Exelixis, Inc. (NASDAQ:EXELFree Report) by 8.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 47,150 shares of the biotechnology company’s stock after selling 4,325 shares during the period. Peloton Wealth Strategists’ holdings in Exelixis were worth $1,131,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of EXEL. Fisher Asset Management LLC grew its position in Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 728 shares during the last quarter. Treasurer of the State of North Carolina grew its position in Exelixis by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company’s stock worth $3,176,000 after purchasing an additional 738 shares during the last quarter. Quadrant Capital Group LLC grew its position in Exelixis by 10.8% during the 4th quarter. Quadrant Capital Group LLC now owns 7,709 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 750 shares during the last quarter. Jennison Associates LLC grew its position in Exelixis by 0.5% during the 4th quarter. Jennison Associates LLC now owns 164,200 shares of the biotechnology company’s stock worth $3,939,000 after purchasing an additional 815 shares during the last quarter. Finally, Seven Eight Capital LP grew its position in Exelixis by 4.0% during the 4th quarter. Seven Eight Capital LP now owns 22,637 shares of the biotechnology company’s stock worth $543,000 after purchasing an additional 872 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Performance

Shares of EXEL traded down $0.21 during trading hours on Friday, hitting $21.75. The stock had a trading volume of 428,958 shares, compared to its average volume of 2,171,468. The firm has a 50-day moving average price of $22.06 and a 200 day moving average price of $22.33. Exelixis, Inc. has a fifty-two week low of $18.64 and a fifty-two week high of $24.34. The firm has a market capitalization of $6.59 billion, a price-to-earnings ratio of 34.31, a PEG ratio of 0.54 and a beta of 0.56.

Exelixis (NASDAQ:EXELGet Free Report) last posted its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.16). The company had revenue of $425.23 million for the quarter, compared to analyst estimates of $461.04 million. Exelixis had a return on equity of 8.85% and a net margin of 11.10%. The business’s revenue was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.12 earnings per share. As a group, analysts predict that Exelixis, Inc. will post 1.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Exelixis news, Director Jack L. Wyszomierski sold 10,923 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $21.37, for a total transaction of $233,424.51. Following the completion of the transaction, the director now directly owns 338,948 shares in the company, valued at $7,243,318.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Jack L. Wyszomierski sold 10,923 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $21.37, for a total transaction of $233,424.51. Following the completion of the sale, the director now owns 338,948 shares of the company’s stock, valued at $7,243,318.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director George Poste sold 11,686 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total transaction of $244,938.56. Following the sale, the director now directly owns 213,907 shares of the company’s stock, valued at approximately $4,483,490.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,101 shares of company stock worth $1,121,789. Company insiders own 2.85% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on EXEL. JMP Securities reissued a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a research report on Wednesday, April 10th. StockNews.com cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 4th. Barclays cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research note on Thursday, April 11th. Stephens started coverage on shares of Exelixis in a research note on Tuesday, May 14th. They set an “equal weight” rating and a $23.00 price objective for the company. Finally, TD Cowen lifted their price objective on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and an average price target of $26.13.

Check Out Our Latest Analysis on EXEL

Exelixis Company Profile

(Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Featured Articles

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.